Taltz (ixekizumab) vs Stelara (ustekinumab)
Taltz (ixekizumab) vs Stelara (ustekinumab)
Taltz (ixekizumab) and Stelara (ustekinumab) are both injectable biologic medications used to treat moderate to severe plaque psoriasis and psoriatic arthritis, but they target different proteins involved in the inflammatory process. Taltz works by blocking interleukin-17A (IL-17A), a cytokine that plays a role in inflammation and is thought to be involved in the development of psoriatic disease. In contrast, Stelara targets interleukin-12 and interleukin-23 (IL-12/23), which are also implicated in the inflammatory pathways of psoriasis and psoriatic arthritis. The choice between Taltz and Stelara should be made in consultation with a healthcare provider, taking into account the individual's medical history, the presence of comorbidities, and the specific indications and safety profiles of each medication.
Difference between Taltz and Stelara
Metric | Taltz (ixekizumab) | Stelara (ustekinumab) |
---|---|---|
Generic name | Ixekizumab | Ustekinumab |
Indications | Plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis | Plaque psoriasis, Psoriatic arthritis, Crohn's disease, Ulcerative colitis |
Mechanism of action | Interleukin-17A antagonist | Interleukin-12 and -23 antagonist |
Brand names | Taltz | Stelara |
Administrative route | Subcutaneous injection | Subcutaneous injection, intravenous infusion |
Side effects | Injection site reactions, Upper respiratory tract infections, Nausea, Fungal infections | Upper respiratory infections, Headache, Fatigue, Diarrhea, Injection site reactions |
Contraindications | Hypersensitivity to ixekizumab or any of the excipients | Hypersensitivity to ustekinumab or any of the excipients |
Drug class | Monoclonal antibody | Monoclonal antibody |
Manufacturer | Eli Lilly and Company | Janssen Biotech, Inc. |
Efficacy
Efficacy of Taltz (Ixekizumab) in Treating Psoriasis
Taltz (ixekizumab) is a biologic medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Ixekizumab is a monoclonal antibody that selectively targets interleukin-17A (IL-17A), a cytokine that plays a key role in the pathogenesis of psoriasis. Clinical trials have demonstrated that Taltz can lead to significant skin clearance. In these studies, many patients achieved a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) score within 12 weeks of treatment, and some even achieved PASI 90 or PASI 100, indicating nearly complete or complete clearance of skin lesions.
The long-term efficacy of Taltz has also been evaluated in extension phases of clinical trials, where the therapeutic effects were sustained for many patients over a period of up to 60 weeks. The safety and efficacy of Taltz have been consistent across various demographic and baseline characteristic groups, including patients with different severities of psoriasis and those with or without psoriatic arthritis.
Efficacy of Stelara (Ustekinumab) in Treating Psoriasis
Stelara (ustekinumab) is another biologic medication approved by the FDA for the treatment of moderate to severe plaque psoriasis in adults. Ustekinumab works by targeting interleukins 12 and 23, which are believed to be involved in inflammatory and immune responses, including the inflammation that occurs in psoriasis. Clinical trials have shown that Stelara can produce significant improvement in patients with plaque psoriasis. A substantial proportion of patients treated with Stelara achieved PASI 75 within 12 weeks, and further improvements were often observed with continued treatment.
Long-term studies have supported the sustained efficacy of Stelara, with many patients maintaining their treatment response for over a year. Additionally, Stelara has been shown to improve quality of life and is generally well-tolerated by patients. The drug's dosing schedule, which starts with an initial dose followed by a second dose four weeks later and then maintenance doses every 12 weeks, may be convenient for patients compared to the more frequent dosing requirements of some other biologics.
Regulatory Agency Approvals
Taltz
Stelara
Access Taltz or Stelara today
If Taltz or Stelara are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us